Global vision impairment and blindness persist as substantial socio-economic challenges, with an estimated rate of one child losing their sight every minute. Corneal diseases rank among the top causes of blindness, with corneal transplants from human donors being the primary treatment. However, the need for cadaveric human corneas significantly outstrips the supply, resulting in millions of patients worldwide remaining untreated and blind each year. The recent pandemic has further intensified these issues, making the current treatment model untenable. Despite the scarcity of options, only a select few artificial corneas are deemed fit for human use. Regrettably, these alternatives are plagued with problems such as infection susceptibility, optical failure, and biocompatibility issues during the regeneration phase. To counter these obstacles, we are in the process of creating a nanotechnology toolbox intended for integration with biosynthetic corneas. This pioneering strategy is designed to mitigate infection risks and boost the regenerative capacity of artificial corneas. This talk will highlight our progress in developing customized implants, each tailored to specific disease conditions. Our research` indicates that these implants not only prevent infections but also promote regeneration. Additionally, the inclusion of theranostic features enables non-invasive tracking of the healing process, providing bespoke solutions for patients. Our efforts signify a hopeful stride towards surmounting the constraints of existing artificial cornea technologies and delivering efficient, patient-centric treatments.